Bootstrap Bio and Manhattan Genomics, which were pursuing human embryo editing to prevent serious disease, have shut down.
At Web Summit Qatar, AI-powered biotech startups describe how automation, data, and gene editing are filling labor gaps in drug discovery and rare disease treatment.